Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 neoadjuvant GAS chemotherapy for biological borderline resectable pancreatic cancer
jRCTs061180009Phase 2Active, not recruiting
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, gemcitabine and tegafur in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC). Primary endpoints: Two-year overall survival rate and Median overall survival. Started Mar 2019; status: active, not recruiting.
02
Drugs
paclitaxelgemcitabinetegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCTs061180009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180009.